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Previously, we showed that the Vpu protein from subtype C human immunodeficiency virus type 1 (HIV-1) was efficiently targeted to the cell
surface, suggesting that this protein has biological properties that differ from the well-studied subtype B Vpu protein. In this study, we have further
analyzed the biological properties of the subtype C Vpu protein. Flow cytometric analysis revealed that the subtype B Vpu (strain HXB2) was
more efficient at down-regulating CD4 surface expression than the Vpu proteins from four subtype C clinical isolates. We constructed a simian-
human immunodeficiency virus virus, designated as SHIVSCVpu, in which the subtype B vpu gene from the pathogenic SHIVKU-1bMC33 was
substituted with the vpu from a clinical isolate of subtype C HIV-1 (strain C.96.BW16B01). Cell culture studies revealed that SHIVSCVpu
replicated with slightly reduced kinetics when compared with the parental SHIVKU-1bMC33 and that the viral Env and Gag precursor proteins were
synthesized and processed similarly compared to the parental SHIVKU-1bMC33. To determine if substitution of the subtype C Vpu protein affected
the pathogenesis of the virus, three pig-tailed macaques were inoculated with SHIVSCVpu and circulating CD4
+ T-cell levels and viral loads were
monitored for up to 44 weeks. Our results show that SHIVSCVpu caused a more gradual decline in the rate of CD4
+ T cells in pig-tailed macaques
compared to those inoculated with parental subtype B SHIVKU-1bMC33. These results show for the first time that different Vpu proteins of HIV-1
can influence the rate at which CD4+ T-cell loss occurs in the SHIV/pig-tailed macaque model.
© 2007 Elsevier Inc. All rights reserved.Keywords: Vpu; SHIV; Macaques; Pathogenesis; Subtype C HIV-1; CD4+ T-cell depletionIntroduction
All the naturally occurring primate lentiviruses encode for
Tat, Rev, Nef, Vif and Vpr accessory proteins. In addition to
these accessory proteins, human immunodeficiency virus type 1
virus (HIV-1) and a select number of simian immunodeficiency
virus (SIV) isolates (SIVcpz, SIVden, SIVgsn, SIVmon, SIVmus)
also encode for a Vpu protein (Barlow et al., 2003; Courgnaud⁎ Corresponding author. Fax: +1 913 588 2710.
E-mail address: estephen@kumc.edu (E.B. Stephens).
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doi:10.1016/j.virol.2007.09.015et al., 2002, 2003; Dazza et al., 2005; Huet et al., 1990). The
Vpu protein is a small transmembrane phosphoprotein synthe-
sized off the same mRNA as the Env precursor and has two
known functions within the cell (Schwartz et al., 1990;
Maldarelli et al., 1993). Vpu is known to interact with the
CD4 molecule within the rough endoplasmic reticulum (RER)
and re-translocate the protein to the proteasome for degradation
(Fujita et al., 1997; Schubert et al., 1998). By removing the
CD4, it permits unbound gp160 to be transported to the cell
surface and incorporated into the budding virion (Willey et al.,
1992). Previous studies have shown that the interaction of the
Fig. 1. Comparison of the Vpu sequences in SHIVKU-1bMC33 and SHIVSCVpu.
87M.S. Hill et al. / Virology 371 (2008) 86–97subtype B Vpu with the CD4 molecule is dependent on the
presence of two casein kinase II (CK-II) phosphorylation sites
(Paul and Jabbar, 1997). The Vpu protein also enhances virion
release from infected cells (Klimkait et al., 1990). Although the
mechanism of enhanced virion release is unknown, some
investigators have linked this property of Vpu to the
transmembrane domain and its ion channel properties (Cordes
et al., 2001; Ewart et al., 1996; Grice et al., 1997; Park et al.,
2003; Schubert et al., 1996a,b). Other investigators have shown
that the certain ion channel-blocking compounds could inhibit
the ion channel activity of Vpu (Ewart et al., 2002, 2004).
Because SIVmac strains commonly used in pathogenicity
studies do not encode for the Vpu protein, we have used the
pathogenic simian human immunodeficiency virus (SHIV),
which has the tat, rev, vpu and env genes of HIV-1 in a genetic
background of the SIVmac239, to analyze the role of Vpu in
pathogenicity. Infection with these pathogenic SHIVs results in
high viral loads, a rapid loss of CD4+ T cells within 1 month of
infection, and severe depletion within lymphoid organs such as
the thymus, lymph nodes and spleen. Using pathogenic
molecular clones that express altered Vpu proteins, we showed
that both the transmembrane domain and cytoplasmic domains
of the Vpu protein contribute to the severe CD4+ T-cell loss in
these macaques (Singh et al., 2003; Hout et al., 2004, 2005).
To date, all studies assessing the role of Vpu in macaques
have been performed using the well-studied subtype B Vpu
protein from a laboratory-adapted HIV-1 isolate. Recently, we
reported that the subtype C Vpu proteins were efficientlyFig. 2. The subtype C Vpu is less efficient at down-regulating surface CD4 than
the subtype B Vpu protein. HeLa CD4+ cells were transfected with plasmids
pcegfp, pcvpuegfp, pcvpuSCegfp1 or pcvpuSCegfp21301, pcvpuSCegfpBW06.
H51, or pcvpuSCegfpBW04.07. At 48 h, live cells were immunostained for CD4.
Cells expressing EGFP or EGFP fusion proteins were assessed for CD4 down-
regulation using flow cytometry.transported to the cell surface, indicating that the subtype C Vpu
protein may have biological properties that differ from the better
studied subtype B Vpu protein (Pacyniak et al., 2005). In this
study, we report that the subtype C Vpu protein is less efficient
at down-regulating CD4 from the cell surface than the subtype
B Vpu. Using the pathogenic molecular clone, SHIVKU-1bMC33,
we report on the construction of a SHIV in which the subtype B
vpu was exchanged with the vpu from a clinical isolate of
subtype C HIV-1 (SHIVSCVpu). Our results show that following
inoculation into macaques, SHIVSCVpu had a decreased rate of
CD4+ T-cell loss compared with the parental SHIVKU-1bMC33.
These results show for the first time that different Vpu proteins
can influence the rate of CD4+ T-cell loss in the SHIV/macaque
model.
Results
CD4 down-regulation by subtype B and C Vpu proteins
The sequence of the subtype B and C Vpu proteins analyzed
in this study are shown in Fig. 1. Previously, we showed that
fusion of the Vpu protein to enhanced green fluorescent protein
(EGFP) still resulted in the ability to down-modulate cell
surface CD4 (Hout et al., 2005, 2006; Singh et al., 2003). We
analyzed the efficiency of cell surface CD4 down-regulation by
the subtype B and C Vpu fusion proteins. HeLa CD4+ cells
were transfected with vectors expressing either the subtype B or
C Vpu fusion proteins. At 48 h post-transfection, live cells were
immunostained for CD4 and analyzed by flow cytometry to
measure the intensity of cell surface CD4 expression. As shown
in Fig. 2, the cells transfected with the vector expressing the
subtype B fusion (VpuEGFP) consistently down-regulated CD4
more efficiently (pb0.008) than cells transfected with the vector
expressing the subtype C Vpu fusion protein (VpuSCEGFP1).Fig. 3. The Vpu protein is expressed in C8166 cells infected with SHIVSCVpu.
C8166 cells were infected with SHIVSCVpu or SHIVKU-1bMC33 for 5 days. The
cells were starved for methionine/cysteine for 2 h and then radiolabeled for 12 h
with 35S-methionine/cysteine. Cell lysates were prepared as described in the text
and Vpu proteins immunoprecipitated with an antisera generated against the
cytoplasmic domain of the subtype B Vpu protein or the subtype C Vpu protein.
(Lane 1) Vpu proteins immunoprecipitated from SHIVKU-1bMC33-inoculated
cultures. (Lane 2) Vpu proteins immunoprecipitated from SHIVSCVpu-inoculated
cultures. (Lane 3) Vpu proteins immunoprecipitated from uninfected cultures.
Fig. 4. Pulse-chase analysis of the SHIVSCVpu. To determine whether viral structural proteins were released with reduced efficiency in SHIVSCVpu-inoculated cultures,
C8166 cells were with inoculated 103 TCID50 of either SHIVSCVpu or SHIVKU-1bMC33. At 7 days post-infection, the medium was removed and infected cells were
incubated in methionine/cysteine-free medium for 2 h. The cells were radiolabeled for 30 min with 1 mCi per ml of 35S-Translabel (methionine and cysteine, ICN
Biomedical, Costa Mesa, CA) and the radiolabel chased for various periods (0–6 h) in DMEM containing 100× unlabeled methionine/cysteine. SHIV proteins were
immunoprecipitated from cell lysates using plasma pooled from several pig-tailed monkeys infected previously with SHIVas described in the Materials and methods
section. Uninfected C8166 cells, radiolabeled and chased for 6 h, served as a negative control (lane C). All immunoprecipitates were collected on protein A Sepharose,
the beads washed three times with RIPA buffer, and the samples resuspended in sample reducing buffer. Samples were boiled and the SHIV specific proteins analyzed by
SDS–PAGE (10% gel). Proteins were then visualized by standard autoradiographic techniques. (A) Results of pulse-chase analysis of viral proteins immunoprecipitated
from SHIVKU-1bMC33 infected cell lysates. (B) Results of pulse-chase analysis of viral proteins immunoprecipitated from SHIVSCVpu-infected cell lysates.
Fig. 5. The kinetics of replication of SHIVKU-1bMC33 and SHIVSCVpu in C8166 cell
cultures. Cultures of C8166 cells were inoculated with either SHIVKU-1bMC33 or
SHIVSCVpu as described in the text. Aliquots of the culture medium were assayed
for the presence of p27 antigen. The growth curves were performed in triplicate.
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fusions to EGFP (IN21301, BW04.07, and BW06.H51) fusion
proteins to down-regulate CD4 surface expression. As shown in
Fig. 2, all three Vpu proteins were significantly less efficient
(pb0.05) at preventing CD4 surface expression compared to the
HXB2 Vpu protein.
The SHIVSCVpu virus expresses the Vpu protein within infected
cells
We analyzed the expression of the Vpu protein in C8166
cultures inoculated with parental SHIVKU-1bMC33 or SHIVSCVpu.
Cultures were inoculated with equivalent amounts of virus and at
5 days post-inoculation, cells were radiolabeled and Vpu pro-
teins immunoprecipitated from cell lysates. As shown in Fig. 3, a
protein with an Mr of 16,000 was immunoprecipitated from
SHIVKU-1bMC33-inoculated cultures. A Vpu protein was also
immunoprecipitated from SHIVSCVpu-inoculated C8166 cultures
with a slightly slower mobility in SDS–PAGE, which may be due
to the larger size (85 vs. 82 amino acids) of the subtype C Vpu
protein (Fig. 3).
Pulse-chase analysis reveals that SHIVSCVpu precursor proteins
are synthesized and processed with similar kinetics compared
to parental SHIVKU-1bMC33
Previous studies have shown that Vpu expression results in
more efficient release of virus particles from infected cells. We
used pulse-chase analysis to determine if substitution of the
subtype B vpu for the subtype C vpu would result in similar
release of viral proteins from infected cells. These results
indicate that the substitution of the subtype B vpu for thesubtype C vpu did not significantly alter the processing of Gag
and Env precursor proteins (Fig. 4).
SHIVSCVpu replicates with delayed kinetics and is less
cytopathic compared to parental SHIVKU-1bMC33
Weanalyzed the growth kinetics of the parental SHIVKU-1bMC33
and the SHIVSCVpu following inoculation of C8166 cell cultures.
Fig. 6. Electron microscopy examination of C8166 cells inoculated with SHIVKU-1bMC33 or SHIVSCVpu. C8166 cells were inoculated with either SHIVSCVpu or
SHIVKU-1bMC33 for 7 days. Cells were washed three times with PBS and processed for electron microscopy as described in the Materials and methods section.
(A) C8166 cells inoculated with SHIVSCVpu. (B) C8166 cells inoculated with parental SHIVSCVpu showing a virus particle maturing at the cell surface. (C) C8166 cells
inoculated with parental SHIVKU-1bMC33. (D) C8166 cells inoculated with parental SHIVKU-1bMC33 showing a particle maturing at the cell surface.
Fig. 7. Envelope incorporation in SHIVKU-1bMC33 and SHIVSCVpu. C8166 cells
were inoculated with either SHIVKU-1bMC33 or SHIVSCVpu for 6 days. At day 6,
cultures were labeled as described in the Materials and methods section. The
virus culture supernatants were centrifuged through a 20% sucrose cushion and
lysed for immunoprecipitation. SHIV proteins were immunoprecipitated from
cell lysates using plasma pooled from several pig-tailed monkeys infected
previously with SHIV as described in the Materials and methods section.
Uninfected C8166 cells served as a negative control. All immunoprecipitates
were collected on protein A Sepharose, the beads were washed three times with
RIPA buffer, and the samples were resuspended in sample reducing buffer.
Samples were boiled and the SHIV specific proteins analyzed by SDS–PAGE
(10% gel). (Lane 1) Immunoprecipitated SHIV proteins from SHIVSCVpu. (Lane
2) Immunoprecipitated SHIV proteins from uninfected C8166 cells. (Lane 3)
Immunoprecipitated SHIV proteins from SHIVKU-1bMC33. Molecular weight
markers are to the right of the gel.
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compared to the parental SHIVKU-1bMC33.While the amount of p27
released appeared to be delayed by 2 days, the rate of p27 release
from 7 to 10 days was reproducibly similar. At the end of the
experiment, the amount of p27 released from SHIVSCVpu-
inoculated cultures was 86% of the p27 found in the parental
SHIVKU-1bMC33-inoculated cultures. However, the kinetics of p27
release was different from C8166 cells inoculated with SHIVTM,
which has a scrambled transmembrane domain (Hout et al., 2005),
or from cultures inoculated with novpuSHIVKU-1bMC33, which
lacks the vpu sequences prior to the env (Stephens et al., 2002).We
also compared the pattern of virusmaturation in cultures inoculated
with parental SHIVKU-1bMC33 and SHIVSCVpu using electron
microscopy. The results shown in Fig. 6 indicate that SHIVSCVpu
matures from the cell surface similar to parental SHIVKU-1bMC33.
The reduced kinetics of p27 release were also reflected in the time
before the appearance of syncytial cytopathology.With the parental
SHIVKU-1bMC33, cytopathology generally appears 3 to 4 days post-
inoculation, whereas SHIVSCVpu-inoculated cultures displayed
cytopathology starting 5 to 6 days post-inoculation. Additionally,
the syncytia formation did not appear to be as extensive as
SHIVKU-1bMC33, suggesting that this subtype C Vpu protein could
influence the ability to form syncytia in culture (data not shown).
The subtype C Vpu does not influence the incorporation of
envelope glycoprotein into viral particles
We determined if substitution of the subtype B vpu with the
subtype C vpu would influence the incorporation of Env into
viral particles. SHIVKU-1bMC33 and SHIVSCVpu were used to
infect C8166 cells and radiolabeled at 6 days post-inoculation.
The virus containing culture medium was harvested and virus
pelleted through a 20% sucrose cushion. The pellet was lysedand the SHIV proteins immunoprecipitated using an anti-SHIV
serum. The immunoprecipitated proteins were analyzed by
SDS–PAGE and densitometry to determine the ratio of Gag p27
90 M.S. Hill et al. / Virology 371 (2008) 86–97protein to Env gp120. As shown in Fig. 7, the ratio of
immunoprecipitated p27 to gp120 was approximately equal for
the two viruses SHIVKU-1bMC33 (ratio 4.31) than for SHIVSCVpu
(ratio 4.89), suggesting that exchanging the subtype B vpu for
the subtype C vpu did not influence the level of Env (gp120)
associated with particles.
The rate of CD4+ T-cell loss was decreased and viral loads
lower in SHIVSCVpu inoculated macaques
To determine whether the SHIVSCVpu was capable of causing
disease in pig-tailed macaques, three macaques (CX56, CX57,Fig. 8. Circulating CD4+ T-cell levels and plasma viral loads following inoculation of m
Tcells inmacaques (CX56,•; CX57,♦; and PLG2,Δ) following inoculationwith SHIV
CM4G, ▪; and CM4K, Δ) following inoculation with SHIVKU-1bMC33. (C) Plasma vi
SHIVSCVpu. (D) Plasma viral RNA levels in three macaques (2000,•; 2001,▪; and C
RT-PCR and Taqman probe homologous to the SIV gag gene. Standard curves weand PLG2) were inoculated with SHIVSCVpu and CD4
+ T cells,
and viral loads followed for up to 44 weeks. Macaque CX56 and
CX57 were euthanized in a moribund condition at 36 and
44 weeks post-inoculation. Macaque PLG2 was euthanized at
40 weeks post-inoculation following development of severe
enteritis. The circulating CD4+ T-cell levels are shown in Fig. 8A
and indicate that all three macaques developed a gradual decline
in the levels of circulating CD4+ Tcells during the course of their
infection. The rate of circulating CD4+ T-cell loss in macaques
inoculated with SHIVSCVpu was clearly decreased compared to
parental SHIVKU-1bMC33 (Fig. 8B). The rate of CD4
+ T-cell loss
was found to be statistically significant (pb0.01). We also foundacaques with SHIVSCVpu and SHIVKU-1bMC33. (A) The levels of circulating CD4
+
SCVpu. (B) The levels of circulating CD4
+ Tcells in fourmacaques (2000,•; 2001,♦;
ral RNA levels in macaques (CX56, •; CX57, ♦; and PLG2, Δ) inoculated with
M4K,Δ) inoculated with SHIVKU-1bMC33. Samples were subjected to real time
re generated using five dilutions of viral RNA of known concentration.
91M.S. Hill et al. / Virology 371 (2008) 86–97that the early peak viral loads (between 1 and 3 weeks) in
macaques inoculatedwith SHIVSCVpuwere approximately 10-fold
less than in macaques inoculated with the parental SHIVKU-1bMC33
(Figs. 8C and D).
Sequence analysis of the vpu gene isolated from SHIVSCVpu
inoculated macaques
We analyzed the sequence of the vpu genes amplified from
PBMC at different times post-inoculation and three lymphoid
tissues (spleen, thymus and mesenteric lymph node) at necropsy.
In all three macaques, we found scattered amino acid substitutions
at different times post-inoculation but no consensus amino acid
substitutions (data not shown).
The pathology in lymphoid organs at necropsy was similar to
the parental SHIVKU-1bMC33
We examined the histological sections from tissues of
macaques inoculated with SHIVSCVpu at necropsy and compared
the lesions to those observed following inoculation with parentalFig. 9. Histopathology associated with SHIVSCVpu infection of macaques. Hematoxyli
(C and D) and spleen (E and F) from a non-infected age-matched macaque (A, C, aSHIVKU-1bMC33. No significant histological lesions were observed
in the 15 regions of the brain and spinal cord (central nervous
system; CNS), the heart, liver, lungs, kidney, or pancreas. The lack
of histological lesions in the CNS is not surprising as the parental
SHIVKU-1bMC33 is not a neuropathogenic virus. As shown in
Fig. 9, the SHIVSCVpu-inoculated macaque CX56 developed
severe atrophy of the thymus, marked lymphoid depletion with
little follicular activity in the lymph nodes, andmoderate lymphoid
depletion in the spleen. These lesions were similar to that seen in
macaques inoculated with parental SHIVKU-1bMC33. Macaque
CX57 developed similar lymphoid depletion in the thymus and
lymph nodes but no significant lesions were found in the spleen.
Macaque PLG2 developed severe enteritis and protracted diarrhea.
This macaque developed thymus atrophy and moderate depletion
in the lymph nodes. The distribution of virus in the various visceral
organs was determined by PCR for viral gag and 2-LTR
sequences. All three macaques were positive for gag sequences
in all 13 visceral organs despite exsanguination with 1 l of saline
(data not shown). We also examined tissue RNA for the presence
of viral RNA. As shown in Fig. 10, viral RNA sequences were
detected in RNA sequences isolated from 7 of 13, 7 of 13, and 6 ofn and eosin stains of sections from the thymus (A and B), mesenteric lymph node
nd E) and macaque CX56 (B, D, and F).
Fig. 10. Distribution of virus in macaques CX56, CX57, and PLG2. Viral
sequences were amplified using RT-PCR from RNA samples from visceral
organs frommacaques CX56 (A), CX57 (B), and PLG2 (C). The order of the gels
are: (A) Positive control (RNA from SHIV infected C8166 cells). (Lane 2)
Negative control-lymph node from an uninoculated macaque. (Lane 3) Heart.
(Lane 4) Liver. (Lane 5) Lung. (Lane 6) Kidney. (Lane 7) Pancreas. (Lane 8)
Salivary gland. (Lane 9)Mesenteric lymph node. (Lane 10) Axillary lymph node.
(Lane 11) Inguinal lymph node. (Lane 12) Small intestine. (Lane 13) Spleen.
(Lane 14) Thymus. (Lane 15) Tonsil.
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Themajority of the tissue RNAs that were positive for the presence
of viral RNA sequences were the lymphoid organs. We also
analyzed the RNA samples of tissues from 15 regions of the CNS
for viral RNA sequences. Macaques CX56, CX57, and PLG2 had
no regions of the brain and spinal cord that were positive for viral
RNA sequences (data not shown).
Discussion
The vast majority of HIV-1 infections are in Sub-Saharan
Africa, where an estimated 60–70% of infected people reside
(WHOwebsite). Within the HIV-1 groupM pandemic, subtype C
has increased in prevalence over the past 10 years, accounting for
approximately 50% of the infections worldwide (Essex, 1999;
Hemelaar et al., 2006; Takebe et al., 2004), and is most prominent
in east Africa, south Africa, India and parts of China. In one study,
both NSI/R5 and SI/X4 subtype C HIV-1 isolates were found to
be significantly less fit in PBMC competition assays compared to
all other group M isolates of the same phenotype (Ball et al.,
2003). More recently, in a study that evaluated the replicative
fitness of representative strains from subtypes A, B, C, D and
CRF01_AE, the subtype C viruses had less replicative fitness in
PBMC compared to the other subtypes. However, the subtype C
isolates still replicated 100-fold higher than HIV-2 or group O
isolates (Arien et al., 2005, 2007). Although less fit for replication
in PBMC, the subtype C viruses were found to be similar to
subtype B viruses for replicative fitness in skin-derived
Langerhans cells, suggesting that these viruses might be more
efficiently transmitted (Ball et al., 2003). In a recent study,
subtype C HIV-1 was associated with the increased vaginalshedding of virus (John-Stewart et al., 2005). These data suggest
that the relatively poor replication efficiency of subtype C in
PBMCs (and possibly lymphoid organs) may be related to slower
disease progression, hence, longer survival of the human host,
which in turn could lead to increased time for transmission (Ball
et al., 2003; Quinones-Mateu et al., 2001).
The subtype C Vpu protein has structural motifs that differ
from the well-studied subtype B Vpu protein, and these may be
associated with different biological properties of these two
proteins (Hout et al., 2004). The subtype C Vpu proteins have
an additional potential CK-II site (TMVD) downstream from the
two consensus sites. A second, potentially interesting sequence
motif unique to the subtype C Vpu proteins is a canonical
dileucine motif (E/D-X-X-X-L-L/I) towards the carboxyl termi-
nus of the Vpu protein. An acidic residue located at position 4, 5,
or 6 upstream of the dileucine motif has been shown by inves-
tigators to be required for the efficient internalization of several
proteins (Bonifacino and Traub, 2003). Dileucine motifs are
known to interact with adaptor protein complexes AP-1, AP-2,
and AP-3, resulting in the recruitment of cargo into clathrin-
coated pits and clathrin-coated vesicles (Bonifacino and Traub,
2003). Previous studies have implicated dileucine-based motifs in
the sorting ofmembrane proteins to cellular sites such as the trans-
Golgi network (TGN), endosomes, lysosomes, and plasma
membrane (Bonifacino and Traub, 2003). The HIV-1 Nef protein,
associates with the inner side of the cell plasma membrane via its
myristylated amino terminus. Importantly, the HIV-1 Nef, which
also interacts with and down-regulates CD4 from the surface of
infected cells, has a dileucine motif at the carboxyl terminus. This
dileucine motif is required for CD4 down-regulation (Aiken et al.,
1994; Bresnahan et al., 1998; Craig et al., 1998; Goldsmith et al.,
1995). Our analysis indicates that the subtype C Vpu proteins
from Indian and African subtype C isolates have “DM-GRLRLL”
or “DMDGLRLL” motifs close to the carboxyl terminus, which
closely fit the consensus motif described above. Thus, if these
sequences are found to be responsible for altered biological
properties, it has potential significance to HIV-1 pathogenesis,
since subtype C isolates represent approximately 50% of the HIV-
1 infections worldwide (Takebe et al., 2004).
In addition to differences regarding structural motifs, the
subtype B and C have different biological properties. Using a
reporter system that fused the Vpu protein to enhanced green
fluorescent protein (EGFP), we previously showed that the
subtype B Vpu protein is predominantly localized in the Golgi
complex of the cell while the subtype C Vpu protein was
transported to the cell plasma membrane (Pacyniak et al., 2005).
In our data presented here, we used flow cytometric analysis to
compare the efficiency of subtype C Vpu proteins at down-
regulating CD4 from the cell surface. These studies revealed
that the efficiency of subtype B Vpu CD4 down-regulation was
statistically different than four subtype C Vpu proteins. These
results indicate an additional difference in the biological
properties of the subtype C and B Vpu proteins.
In previous studies using a pathogenic molecular clone of sim-
ian–human immunodeficiency virus known as SHIVKU-1bMC33,
we showed that the subtype B Vpu protein contributes to the
profound CD4+ T-cell loss following inoculation into pig-tailed
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et al., 2002). These studies showed that the two casein kinase II
sites and the transmembrane domain contribute to the rapid CD4+
T-cell loss following inoculation into macaques. Furthermore, we
showed that the Vpu transmembrane domain could be replaced
with the TM domain of the M2 protein of influenza A virus and
retain pathogenicity in pig-tailed macaques (Hout et al., 2006).
Thus, thismodel has been useful in themolecular analysis of those
domains of Vpu that are necessary for disease progression.
Attempts have been made to construct pathogenic SHIVs
expressing the env gene from subtype C HIV-1 (Chen et al.,
2000; Ndung'u et al., 2001. In one of these studies, investigators
constructed a SHIV expressing an R5 envelope glycoprotein
(including the C-terminal end of the Vpu protein which contains
the most amino acid divergence between the subtype B and C
Vpu proteins) from a subtype C HIV-1 isolate (strain CHN19).
These investigators found that this virus was capable of
replicating in pig-tailed macaque PBMC but not rhesus
macaque PBMC. They observed that with serial passage in
pig-tailed macaques, the virus replicated more efficiently. How-
ever, these macaques never developed significant CD4+ T-cell
loss and functionality of this chimeric Vpu was not determined
(Chen et al., 2000). In another study, a SHIVwas constructed with
the majority of the subtype C env gene (the gp120 region starting
just past the vpu ORF and part of gp41) into a SHIV89.6P based
virus (Ndung'u et al., 2001). This virus was found to replicate in
both rhesus and pig-tailed macaques. This virus was capable of
replicating to high peak viral loads in rhesusmacaques but did not
result in significant CD4+ T-cell loss. In our studies presented
here, we have concentrated on the contribution of the subtype C
Vpu in the pathogenic SHIV/macaque model system. We
hypothesized that if a SHIV expressing a Vpu protein from
another subtype of HIV-1 (in this case, subtype C) still resulted in
severe CD4+ T-cell loss, it would suggest that the divergent
sequence of this Vpu (particularly the carboxyl terminus) was not
a factor in disease progression. Our results presented here indicate
that a SHIV constructed with the Vpu from a subtype C Vpu
(SHIVSCVpu) significantly differed in the rate of CD4
+ T-cell loss
compared to parental pathogenic SHIVKU-1bMC33. As SHIVSCVpu
and parental SHIVKU-1bMC33 are identical with the exception of
the vpu gene and the overlapping env sequences (which do not
appear to significantly affect envelope glycoprotein synthesis and
processing), these results suggest that the efficiency of the CD4
down-regulation by the Vpu protein correlates with the rate of
CD4+ T-cell loss in vivo. A potential caveat of this study is that the
expressed Vpu may not be reflective of all subtype C Vpu
proteins. Although a valid concern, the subtype C Vpu protein we
used to construct SHIVSCVpu is similar to other subtype C Vpu
sequences from Botswana (data not shown). Further, our
experiments examining the down-regulation of CD4 from the
cell surface revealed similarities among the four subtype C Vpu
proteins (both from Botswana and India) when compared to the
HXB2. Whether the decreased rate of CD4+ T-cell loss in
SHIVSCVpu-inoculated macaques was due to the rate of turnover
of the Vpu protein in cells in vivo, the magnitude of CD4 down-
regulation or the ability to influence virus release within infected
cells remains to be determined.Materials and methods
Cells, viruses, and vectors
C8166 cell line was used as the indicator cells to measure
infectivity and cytopathicity of the viruses used in this study. C8166
cells were maintained in RPMI-1640, supplemented with 10mM
Hepes buffer pH 7.3, 2 mMglutamine, 5 μg per ml gentamicin and
10% fetal bovine serum (R10FBS). The 293 cell line was
maintained inDulbecco'sminimal essentialmedium supplemented
with 10% fetal bovine serum and 5 μg per ml gentamicin. The
derivation and pathogenicity of SHIVKU-1bMC33 has been described
(McCormick-Davis et al., 2000b; Singh et al., 2003; Stephens et al.,
2002). Vectors expressing the subtype B (pcvpuegfp) and C
(pcvpuscegfp) Vpu proteins fused to enhanced green fluorescent
protein (EGFP) have been previously described (Gomez et al.,
2005; Pacyniak et al., 2005; Singh et al., 2003). In addition to these
two vectors, vectors were constructed as described above that
expressed the vpu from three additional subtype C isolates from
HIV-1 patients (IN21301; C.96BW04.07; and C.96BW06.H51).
Analysis of the efficiency of CD4 down-regulation
For analysis of the efficiency of CD4 down-regulation, HeLa
CD4+ cells were seeded into six-well plates such that at 24 h the
cells would be 70–80% confluent. Cells were transfected with
plasmids expressing EGFP or various Vpu proteins fused to EGFP.
Cultures were monitored for 48 h, then removed from the six-well
plate and stained with PE-Cy5 conjugated anti-CD4 (BD
Bioscience). Cells were analyzed using an LSR II flow cytometer,
determining mean fluorescence intensity (MFI) of PE-Cy5 for
transfected (EGFP positive) and untransfected (EGFP negative)
cells within the same well. An MFI ratio was calculated for each;
EGFP was normalized to 1. Normalized ratios from at least three
separate experiments were averaged and the standard deviation
calculated. All groups were compared using one-way ANOVA
(performed using SAS software, alpha=0.5) to determine variance.
Post hoc analysis was performed using Tukey's HSD test.
Construction of SHIVSCVpu
A plasmid containing the 96BW16B01 env and vpu was used
in a PCRwith oligonucleotides that introduced aNsiI site at the 5′
end of the vpu (5′-GTAATGCATAGTTTAATAGAAAAA-
GTAGAT-3′) and a KpnI site in the env gene (5′-CACAGG-
TACCTATGCTTTAGCATC-3′). The 258-bp amplicon was gel
purified, according to a Millipore isolation protocol, and ligated
into pGEM-T Easy Vector (Promega, Madison, WI). The re-
sulting transformants were screened for an insert and the plasmids
sequenced to ensure that restriction sites as well as the subtype C
vpu was intact. This plasmid was designated as pvpuSC.
Insertion of the subtype C vpu gene into SHIV was accom-
plished in a three-step process. In the first step, the
pUC19ΔSN#12 plasmid, which has the SphI/KpnI fragment of
SHIVKU1bMC33 in a pUC19 background and aNsiI site introduced
at the beginning of the vpu was digested with NsiI/KpnI and gel
purified to remove the NsiI/KpnI fragment (containing the vpu
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KpnI fragment isolated from plasmid pvpuSC using T4 DNA
ligase. The resulting plasmid, pUCvpusc, was sequenced with
M13 reverse primer (M13R) to ensure that tat, rev, subtype C vpu,
and env were intact and no mutations were introduced during the
subcloning process. For introduction of the subtype C vpu into p3′
SHIVKU1bMC33, both pUCvpusc and p3′-SHIVKU1bMC33 were
digested to completion with SphI and KpnI, gel purified, and
ligated as previously described (McCormick-Davis et al., 2000a,b;
Stephens et al., 2002; Singh et al., 2003; Hout et al., 2005,
2006). The resulting plasmid, known as p3′-SHIVSCVpu, was
sequenced with appropriate oligonucleotide primers to insure that
the tat, rev, vpusc and env genes were intact. For the production of
SHIVSCVpu, p3′-SHIVSCVpu, and p5′-SHIV-4 were digested with
SphI overnight, ligated, and used to transfect C8166 cells as
previously described (Hout et al., 2005, 2006; McCormick-Davis
et al., 2000a,b; Singh et al., 2003; Stephens et al., 2002). Stocks
were prepared, titrated in C8166 cells and frozen at −86 °C until
used.
Immunoprecipitation and pulse-chase analysis
To determine if the Vpu protein was expressed in the
SHIVSCVpu-inoculated cultures, C8166 cells were inoculated
with 103 TCID50 of either SHIVSCVpu or SHIVKU-1bMC33. At
5 days post-infection, the medium was removed and infected
cells were incubated in methionine/cysteine-free Dulbecco's
modified Eagle's medium (DMEM) for 2 h. The cells were then
radiolabeled for 12 h with 500 μCi per ml of 35S-Translabel
(methionine and cysteine, MP Biomedical, Costa Mesa, CA).
Cell lysates were prepared by lysing radiolabeled cells in radio-
immunoprecipitation buffer (RIPA: 50 mM Tris–HCl, pH 7.5;
50 mM NaCl; 0.5% deoxycholate; 0.2% SDS; 10 mM EDTA)
on ice for 30 min, and the nuclei removed by centrifugation in a
microcentrifuge. The Vpu proteins were immunoprecipitated
with either a rabbit antiserum directed the subtype B Vpu
cytoplasmic domain (from the NIH AIDS Reagents Branch,
NIH) or a rabbit antiserum directed against the subtype C Vpu
cytoplasmic domain. All immunoprecipitates were collected on
protein A Sepharose, the beads washed three times with RIPA
buffer, and the samples resuspended in sample reducing buffer.
Samples were boiled and the SHIV specific proteins analyzed
by SDS–PAGE. Proteins were visualized by standard autora-
diographic techniques.
For pulse-chase analyses, cultures were inoculated with
either SHIVSCVpu or SHIVKU-1bMC33 as described above. At
7 days post-infection, the medium was removed and infected
cultures were incubated in methionine/cysteine-free Dulbecco's
modified Eagle's medium (DMEM) for 2 h and then
radiolabeled with 1 mCi per ml of 35S-methionine for 30 min.
The radiolabel was chased for various periods in DMEM
containing 100× unlabeled methionine/cysteine. At each time
point, the cell culture medium was clarified (16,000×g) for 30 s.
The supernatant was transferred to a new microfuge tube and
made 1× with respect to RIPA buffer. SHIV proteins were
immunoprecipitated with 10 μl of a pooled serum from several
monkeys that were inoculated with non-pathogenic SHIV-4. Forimmunoprecipitation of cell-associated SHIV proteins, cell
lysates were prepared as described previously (McCormick-
Davis et al., 2000a,b; Hout et al., 2004; Stephens et al., 1995,
1997, 2002) prior to incubation with antiserum. Lysates were
centrifuged in a microcentrifuge to remove nuclei prior to the
addition of antibody. Cell lysates and culture medium were
incubated with antibody for 16 h at 4 °C. Immunoprecipitates
were collected and analyzed as described above.
Analysis of Env incorporation into viral particles
To determine if the exchanging the subtype B and C vpu genes
would affect the incorporation of envelope glycoprotein into viral
particles, virus was partially purified and used in immunopreci-
pitations. Cultures of C8166 cells were inoculated with either
SHIVSCVpu or SHIVKU-1bMC33 for 6 days. Cultures were centri-
fuged at 300×g to pellet the cells and starved for methionine/
cysteine for 2 h. The cells were radiolabeled with 35S-methionine/
cysteine for 12 h. The cultures were centrifuged at 300×g for
5 min to remove the cells and the culture supernatant centrifuged
at 10,000×g for 1 min. The supernatant from this centrifugation
step was layered onto 20% sucrose (prepared in PBS, pH 7.4) and
subjected to centrifugation at 100,000×g for 2 h (SW55Ti rotor,
35,000 rpm) to pellet the virus. The pellet was resuspended in 1×
RIPA buffer and SHIV proteins immunoprecipitated as described
above. The immunoprecipitated proteinswere separated by SDS–
PAGE (10% gel) and visualized by standard autoradiographic
techniques. The ratio ofGag p27 to Env gp120was determined by
densitometry.
p27 growth curve assays
Standard p27 assays (Beckman Coulter, SIV core antigen kit)
were used to assess release of viral particles from cells infected
with SHIVSCVpu or parental SHIVKU-1bMC33. Cultures of 10
6
C8166 cells were inoculated with equivalent amounts infectious
cell free virus (1×103) for 4 h. At the end of 4 h, the cells were
centrifuged at 400×g for 10 min and the pellet washed with 10 ml
of medium. This was repeated two additional times. The cells
were resuspended in RPMI-1640 supplemented with 10% FBS
and antibiotics and this was considered the 0 time point of the
assay. Cultures were incubated at 37 °C and aliquots of the culture
were removed at 0, 1, 3, 5, 7, and 10 days with fresh media added
to cultures at days 3 and 6. The culture medium was separated
from the cells by centrifugation and assayed for p27 according to
the manufacturer's instructions.
Electron microscopy
To determine the site of intracellular maturation, infected cells
were examined by transmission electron microscopy. Cultures of
C8166 cells were inoculatedwith SHIVKU-1bMC33 or SHIVM2 at a
multiplicity of infection of 0.01. Cells were incubated for 7 days at
which time cells were pelleted at 400×g for 10 min. Cells were
washed three times with 10 ml of phosphate buffered saline
(pH 7.4) and fixed in 2% glutaraldehyde overnight at 4 °C. Cells
were postfixed in 2% osmium tetroxide (OsO4) for 1 h. The cells
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alcohols (30–100%) followed by embedding in Embed 812 resin.
Thin sections were cut at 80 A, stained with uranyl acetate and
lead citrate and examined under a JEOL 100CXII transmission
electron microscope.
Macaques and inoculations
Three pig-tailed macaques (CX56, CX57, and PLG2) were
inoculated intravenously with 104 TCID50 of SHIVSCVpu. These
macaques were euthanized at 36 to 44 weeks post-inoculation.
We previously reported on the circulating CD4+ T-cell levels
and virus loads in macaques inoculated with pathogenic
SHIVKU-1bMC33 (Stephens et al., 2002; Singh et al., 2003).
Animals were housed in the AAALAC-approved animal facility
at the University of Kansas Medical Center. Heparinized blood
was collected weekly for 6 weeks, then at 3-week intervals for
the next 6 weeks, and thereafter at monthly intervals.
Processing of blood samples
The PBMCs were prepared by centrifugation on Ficoll-
Hypaque gradients as described previously (Joag et al., 1994,
1996). Ten-fold dilutions of PBMCs (106 cells/ml) were inoculated
into replicate cultures and were examined for development of
cytopathic effects as previously described (McCormick-Davis et
al., 2000b; Stephens et al., 2002). Alterations in CD4+ lymphocytes
after experimental inoculations were monitored sequentially by
flow cytometric analysis (Becton Dickinson). T-lymphocyte
subsets were labeled with OKT4 (CD4; Ortho Diagnostics
Systems, Inc), SP34 (CD3; Pharmingen) or FN18 (CD3; Biosource
International) monoclonal antibodies.
Processing of tissue samples at necropsy
At the time of euthanasia, animals were anesthetized by
administration of 10 mg/kg ketamine (IM) followed by an
intravenous administration of sodium pentobarbital at 20–
30 mg/kg. A laparotomy was performed on the animal
exsanguinated by aortic cannulation. The chest was opened,
the left ventricle cannulated, the right atrium nicked, and the
animal perfused with 1 l of cold pyrogen-free Ringer's saline.
All aspects of the animal studies were performed according to
the institutional guidelines for animal care and use at University
of Kansas Medical Center. At necropsy, tissues from the heart,
kidney, liver, lungs, axillary lymph nodes (LN), mesenteric LN,
inguinal LN, pancreas, salivary gland, small intestine, spleen,
thymus, and tonsil were fixed in 10% neutral buffered formalin
and embedded in paraffin. Sections (5 μm) were stained with
hematoxylin and eosin for routine histological examination by a
veterinary pathologist. In addition, the right half of the brain and
spinal cord were dissected into frontal, motor, parietal, temporal
and occipital cortices, corpus callosum, thalamus, basal ganglia,
midbrain, pons, medulla, cerebellum, cervical, thoracic and
lumbar spinal cord and were also processed as above. In
addition to each of the visceral organs, regions of the CNS were
also frozen in liquid nitrogen for DNA isolation.PCR amplification and sequence analysis of gag
DNA was extracted from the visceral organs and different
regions of the CNS as previously described (McCormick-Davis
et al., 2000b) and used to amplify viral gag sequences. The oligo-
nucleotides used for the first round of amplification were 5′-
GATGGGCGTGAGAAACTCCGTCTT-3′(sense) and 5′-
CCTCCTCTGCCGCTAGATGGTGCTGTTG-3′ (antisense)
corresponding to the region 1052–1075 and 1423–1450 of the
SIVmac239 gag gene, respectively (Regier and Desrosiers, 1990).
The nested SIVmac239 primers used were 5′-GTTGAAGCATG-
TAGTATGGGCAGC-3′ (sense) and 5′-CACCACTAGGTGTC-
TCTGCACTATCTG-3′ (antisense), which are complementary to
bases 1142–1165 and 1356–1382 of SIVmac239, respectively.
We also analyzed tissues for the presence of viral RNA,
indicative of actively replicating virus. RNAwas extracted from
approximately 30 mg of each tissue from each of the visceral
organs using the RNAEasy kit (Qiagen) and the manufacturer's
instructions. RNA samples were digested with DNase I for
30 min. Samples were run on agarose formaldehyde gels before
and after DNase treatment to check for the presence of
contaminating DNA. RNA samples were amplified by using
primers for the SHIV gag gene (using the primers described
above) and the Easy-A One-Tube RT-PCR System (Stratagene,
La Jolla, CA). One microgram of total RNA was used in the
one-step reaction containing the manufacturer's buffer and
enzyme mix, and oligonucleotide primers. The reactions were
performed with an Eppendorf Gradient Thermal Cycler with the
following thermal profile: 42 °C for 30 min, 1 cycle; 94 °C for
5 min, 1 cycle; 94 °C for 30 s, 55 °C for 30 s, and 68 °C for 45 s,
25 cycles. One microliter of the initial reaction mixture was
added to a nested PCR mixture containing gag primers and a
further 35 cycles were performed with the following thermal
profile: 95 °C for 1 min, 55 °C for 2 min, and 72 °C for 5 min, 1
cycle; 95 °C for 30 s, 55 °C for 30 s, 72 °C for 45 s, 33 cycles.
The amplified gag fragment is 240 base pairs.
Plasma virus loads
Plasma viral RNA loads were determined on RNA extracted
from EDTA-treated plasma. Virus was pelleted and RNA
extracted using the Qiagen viral RNA kit (Qiagen, Valencia,
CA). RNA samples were analyzed by real-time RT-PCR using
gag primers and a 5'FAM and 3'TAMRA labeled Taqman
probe that was homologous to the SIV gag gene as previously
described (Hofmann-Lehmann et al., 2000). Standard curves
were prepared using a series of six 10-fold dilutions of viral
RNA of known concentration. The sensitivity of the assay was
100 RNA equivalents per milliliter. Samples were analyzed in
triplicate and the number of RNA equivalents were calculated
per milliliter of plasma.
Sequence analysis of the vpu gene
The vpu was amplified from DNA samples isolated from
several tissues taken at necropsy to examine the sequence of vpu.
For amplification of the vpu, we used oligonucleotide primers 5′-
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GTACCTCTGTATCATATGCTTTAGCAT-3′ (antisense), which
are complementary to nucleotides 5845–5870 and 6393–6420 of
the HIV-1 (HXB2) genome (Ratner et al., 1985), respectively. One
microgram of genomic DNAwas used in the PCR with Taq DNA
polymerase and the conditions described above. For the second
round of amplification, we used oligonucleotide primers 5′-
TTAGGCATCTCCTATGGCAGGAAGAAG-3′ (sense) and 5′
CACAAAATAGAGTGGTGGTTGCTTCCT-3′ (antisense),
which are complementary to nucleotides 5956–5984 and 6386–
6413 of the HIV-1 (HXB2) genome (Ratner et al., 1985), respec-
tively. The conditions for amplification were identical to those
described above. For sequence analysis, the PCR products from
three separate PCRs were separated by electrophoresis in a 1%
agarose gel, isolated, and each PCR reaction directly sequenced.
Cycle sequencing reactions were done using the BigDye Termi-
nator Cycle Sequencing ReadyReactionKit with AmpliTaqDNA
polymerase, FS (PE Applied Biosystems, Foster City, CA) and
sequence detection was conducted with an Applied Biosystems
377 Prism XL automated DNA sequencer and visualized using
the ABI Editview program. Sequences were compared to the
intact sequences from SHIVKU-1bMC33. Sequences showing
differences were confirmed by molecularly cloning the PCR
fragments into pGEM-T EZ vector followed by sequencing as
described above.
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